Drug intelligence / Profile preview

EM1039

Development stage: Preclinical
Lead developer: EpimAb Biotherapeutics
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

EM1039 is a novel trispecific T-cell engager (TCE) currently in preclinical development by EpimAb Biotherapeutics for the treatment of B cell-related autoimmune diseases. Utilizing EpimAb's proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) platform, EM1039 is engineered to facilitate the targeted destruction of pathogenic B-cells by recruiting and activating T-cells. While the specific antigens targeted by the three binding arms of the antibody remain undisclosed, the therapeutic strategy aims to provide a more potent or selective depletion of B-cells compared to existing monoclonal or bispecific therapies. The program is currently undergoing IND-enabling studies to support future clinical trials in autoimmune indications.

Beyond the preview

Go deeper on EM1039.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EM1039.

Explore the full profile